{"id":52984,"date":"2023-01-17T15:02:28","date_gmt":"2023-01-17T14:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/chromadex-shares-promising-findings-from-first-of-its-kind-clinical-study-to-demonstrate-oral-nicotinamide-riboside-nr-supplementation-increases-muscle-mitochondrial-biogenesis\/"},"modified":"2023-01-17T15:02:28","modified_gmt":"2023-01-17T14:02:28","slug":"chromadex-shares-promising-findings-from-first-of-its-kind-clinical-study-to-demonstrate-oral-nicotinamide-riboside-nr-supplementation-increases-muscle-mitochondrial-biogenesis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/chromadex-shares-promising-findings-from-first-of-its-kind-clinical-study-to-demonstrate-oral-nicotinamide-riboside-nr-supplementation-increases-muscle-mitochondrial-biogenesis\/","title":{"rendered":"ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis"},"content":{"rendered":"
\n

\nNR improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in first-ever five-month-long study in monozygotic twin pairs<\/i>\n<\/p>\n

LOS ANGELES–(BUSINESS WIRE)–$CDXC<\/a> #CERP<\/a>–ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances<\/i><\/a> by a team of scientists led by Dr. Eija Pirinen (University of Helsinki and University of Oulu) and Dr. Kirsi Pietil\u00e4inen (University of Helsinki).\n<\/p>\n

<\/a><\/p>\n

\nThe clinical trial was part of the ChromaDex External Research Program (CERP\u2122) and investigated the company\u2019s proprietary Niagen\u00ae ingredient (patented nicotinamide riboside, or \u201cNR\u201d) in 20 BMI-discordant (one leaner, one heavier) identical twin pairs. Results of the study showcase that NR supplementation improved muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition. This is the first published and peer-reviewed clinical study demonstrating an increase in mitochondrial biogenesis following NR supplementation in humans and is consistent with a CERP preclinical study published in Cell Reports<\/i><\/a>, demonstrating NR increased mitochondrial biogenesis in neuronal cells. Additionally at five months, this clinical study marks a milestone as the longest published NR supplementation study to date.\n<\/p>\n

\n\u201cWhile previous preclinical research has demonstrated that increasing NAD+ through precursor supplementation improves the quality and quantity of muscle stem cells, promotes muscle function, increases mitochondrial health and respiration, and has therapeutic effects in mitochondrial and muscle disorders, many of these benefits have yet to be translated in human clinical studies,\u201d said Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. \u201cThis study marks an important milestone in research between NR supplementation and mitochondrial biogenesis.\u201d\n<\/p>\n

\nMitochondria are widely known as the powerhouse of cells and help regulate the metabolic status of skeletal muscle by adapting their size, number, and function in response to exercise, disuse, nutrient availability, aging, and disease. One of these regulatory processes is called mitochondrial biogenesis, which occurs in response to physical stimulation, and is the process by which mitochondria increase their number and size by generating new mitochondria from pre-existing ones. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme critical for this process and is directly tied to mitochondrial health. For example, NAD+ is found in high concentrations in healthy skeletal muscle mitochondria, highlighting its importance in skeletal muscle energy production.\n<\/p>\n

\n\u201cOur findings are a great advance in the field of muscle mitochondrial research, and they encourage us and others to continue to test the impact NR may have on muscle mitochondrial dysfunction,\u201d Dr. Pirinen comments.\n<\/p>\n

\nAbout the study:<\/b>\n<\/p>\n

\nThe investigation was an open-label, parallel-assignment study of 20 BMI-discordant identical twin pairs, with 44% of the study participants female, and 56% male. The study also included a small group of BMI-concordant (same amount of body fat and muscle) identical twin pairs (n=8, 4 twin pairs). All twins from the BMI-discordant pairs were supplemented with NR. Of the BMI-concordant twin pairs, one co-twin was randomized to NR supplementation, while the other co-twin was supplemented with placebo. Featuring identical twin pairs, this unique study design allowed the team to investigate the effect of BMI to NR response in individuals with the same genetic background and would not have been possible in a standard study design featuring individuals with different genetic backgrounds.\n<\/p>\n

\nHighlights from NR supplementation within this study:<\/b>\n<\/p>\n